CSL is a global specialty biotherapeutics company that develops and delivers innovative biotherapies that save lives, and help people with life-threatening medical conditions live full lives. With major facilities in Australia, Germany, Switzerland, United Kingdom and the U.S., CSL employs over 17,000 employees working in more than 30 countries. Innovation is at the heart of everything we do. It is reflected in our creation of state-of-the-art plasma collection and manufacturing facilities, our investment in improving current therapies, finding new indications for existing therapies, and innovating new therapeutic products for unmet needs.
> The CSL Board
> Executive Management
The CSL Group includes CSL Behring incorporating CSL Plasma and Seqirus. CSL Behring is a global leader in biotherapies with the broadest range of quality products in our industry and substantial markets in North America, Europe, Asia and Australia. Seqirus is the world’s no. 2 influenza vaccine provider in sales with operations in more than 20 countries in the US$4 billion global industry.
> CSL Behring website
> Seqirus website
Research & Development
CSL continues to invest in the development of protein-based medicines to treat serious human illnesses. Today, most of our licensed medicines are purified from human plasma. CSL has also built the capabilities required to develop new and innovative products using recombinant technology.
Global R&D activities support CSL’s existing licensed products and development of new therapies that align with our technical and commercial capabilities in immunoglobulins, specialty products, haemophilia and coagulation therapies and breakthrough medicines.
> Product Pipeline
> Recent Highlights
CSL is a leading manufacturer in the plasma protein therapeutics industry, estimated to be worth US$24 billion. CSL is also a major manufacturer in a US$4 billion influenza industry, with 40 years manufacturing experience and sales spanning 27 countries around the globe. Our continuing priority is to develop innovative therapies and programs that make a real and lasting difference to the lives of people who use our products, providing new medicines for unmet needs and continuous improvement of our protein-based therapies. To achieve this, we invest in life cycle management and market development for existing products, as well as longer term, new product development opportunities.
> CSL Behring products
> CSL Behring Australia and Seqirus products
The CSL Group has a combined heritage of outstanding contribution to medicine and human health with more than 100 years experience in the development and manufacture of vaccines and plasma protein biotherapies.
> CSL Behring History
> CSL History